Hengrui Pharmaceutical announced that Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of the company, has received the SHR-1139 injection “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration and will conduct clinical trials for palmoplantar impetigo in the near future. SHR-1139 injection is a bispecific antibody targeting IL-23p19 and IL-36r independently developed by the company. Currently, no similar drugs have been approved for marketing at home or abroad, and the total R&D investment for related projects is about 163 million yuan. The drug will need to complete clinical trials and review before it can be marketed, and there is uncertainty.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.